Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 67% Improvement Relative Risk HCQ for COVID-19  Águila-Gordo et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 416 patients in Spain Lower mortality with HCQ (not stat. sig., p=0.1) c19hcq.org Águila-Gordo et al., Revista Española .., Nov 2020 Favors HCQ Favors control

Mortality and associated prognostic factors in elderly and very elderly hospitalized patients with respiratory disease COVID-19

Águila-Gordo et al., Revista Española de Geriatría y Gerontología, doi:10.1016/j.regg.2020.09.006
Nov 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,900+ studies for 60+ treatments. c19hcq.org
67% lower mortality with HCQ. Retrospective 416 elderly patients in Spain showing adjusted HCQ mortality hazard ratio HR 0.33, p = 0.1.
risk of death, 67.0% lower, RR 0.33, p = 0.10, treatment 151 of 346 (43.6%), control 47 of 70 (67.1%), NNT 4.3, adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Águila-Gordo et al., 11 Nov 2020, retrospective, Spain, peer-reviewed, mean age 84.4, 6 authors.
This PaperHCQAll
Mortalidad y factores pronósticos asociados en pacientes ancianos y muy ancianos hospitalizados con infección respiratoria COVID-19
Daniel Águila-Gordo, Jorge Martínez-Del Río, Virginia Mazoteras-Muñoz, Martín Negreira-Caamaño, Patricia Nieto-Sandoval Martín De La Sierra, Jesús Piqueras-Flores
Revista Española de Geriatría y Gerontología, doi:10.1016/j.regg.2020.09.006
Introducción: La población de mayor edad infectada por COVID-19 presenta una peor evolución clínica, siendo más susceptible a desarrollar manifestaciones graves. Las diferencias entre la población anciana y muy anciana, la mortalidad y los factores pronósticos asociados a la infección por SARS-CoV-2 no han sido suficientemente estudiados. Métodos: Registro observacional de 416 pacientes ancianos ingresados de forma consecutiva por infección respiratoria COVID-19 entre el 1 de marzo y el 30 abril de 2020 en el Hospital General Universitario de Ciudad Real. Se registraron variables clínicas y analíticas, intervenciones terapéuticas y desarrollo de eventos durante el ingreso y tras el alta hasta el 15 de junio de 2020, con el objetivo de analizar la mortalidad y factores pronósticos asociados. Resultados: La edad media fue de 84,43 ± 5,74 a ños. Los pacientes ancianos (entre 75 y 84 a ños) constituyeron un 50,2% de la muestra y los muy ancianos (≥ 85 a ños) el 49,8% restante. En el modelo de regresión de Cox multivariante, el riesgo de mortalidad fue mayor en pacientes muy ancianos (HR = 2,58; IC95%: 1,23-5,38; p = 0,01), hipertensos (HR = 3,45; IC95%: 1,13-10,5; p = 0,03) y con enfermedad renal crónica (HR = 3,86; IC95%: 1,3-11,43; p = 0,02). En cambio, la prescripción de calcioantagonistas (HR = 0,27; IC95%: 0,12-0,62; p = 0,002) y la terapia anticoagulante durante la hospitalización (HR = 0,26; IC95%: 0,08-0,83; p = 0,02) se asociaron con mayor tiempo libre de mortalidad. Conclusiones: Los pacientes muy ancianos, hipertensos y con enfermedad renal crónica presentaron mayor riesgo de mortalidad por infección respiratoria COVID-19. En cambio, el empleo de anticoagulación terapéutica y calcioantagonistas durante el ingreso se asociaron con mayor probabilidad de supervivencia en el seguimiento a corto plazo.
References
Bonanad, García-Blas, Tarazona-Santabalbina, Villanueva, Ayesta et al., Coronavirus: the geriatric emergency of 2020. Joint document of the Section on Geriatric Cardiology of the Spanish Society of Cardiology and the Spanish Society of Geriatrics and Gerontology, Rev Esp Cardiol (Engl Ed)
Brojakowska, Narula, Shimony, Bander, Clinical implications of SARS-CoV-2 interaction with renin angiotensin system: JACC Review Topic of the Week, J Am Coll Cardiol
Casas-Rojo, Santos, Ñez-Cortés, Lumbreras-Bermejo, Ramos-Rincón et al., Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19 Registry, Rev Clin Esp (Barc)
Cheng, Luo, Wang, Zhang, Wang et al., Kidney disease is associated with in-hospital death of patients with COVID-19, Kidney Int
Covino, De Matteis, Santoro, Sabia, Simeoni et al., Clinical characteristics and prognostic factors in COVID-19 patients aged ≥ 80 years, Geriatr Gerontol Int
Danta, Calcium channel blockers: A possible potential therapeutic strategy for the treatment of Alzheimer's dementia patients with SARS-CoV-2 infection, ACS Chem Neurosci
Esler, Esler, Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?, J Hypertens
Fang, Karakiulakis, Roth, Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?, Lancet Respir Med
Gao, Cai, Zhang, Zhou, Zhang et al., Association of hypertension and antihypertensive treatment with COVID-19 mortality: A retrospective observational study, Eur Heart J
Geriatric, Statement of the EuGMS Executive Board on the COVID-19 epidemic
Hewitt, Carter, Vilches-Moraga, Quinn, Braude et al., The effect of frailty on survival in patients with COVID-19 (COPE): A multicentre, European, observational cohort study, Lancet Public Health
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Jin, Bai, He, Wu, Liu et al., Gender differences in patients with COVID-19: Focus on severity and mortality, Front Public Health
Leung, Risk factors for predicting mortality in elderly patients with COVID-19: A review of clinical data in China, Mech Ageing Dev
Liu, Chen, Lin, Han, Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients, J Infect
Nadkarni, Bagiella, Chang, Moreno, Pujadas, Anticoagulation, mortality, bleeding and pathology among patients hospitalized with COVID-19: A single health system study, J Am Coll Cardiol [Internet
Niu, Tian, Lou, Kang, Zhang et al., Clinical characteristics of older patients infected with COVID-19: A descriptive study, Arch Gerontol Geriatr
Paranjpe, Fuster, Russak, Glicksberg, Levin, Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19, J Am Coll Cardiol
Porcheddu, Serra, Kelvin, Rubino, Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China, J Infect Dev Ctries
Solaimanzadeh, Nifedipine and amlodipine are associated with improved mortality and decreased risk for intubation and mechanical ventilation in elderly patients hospitalized for COVID-19, Cureus
Sommerstein, Gräni, Preventing a COVID-19 pandemic: ACE inhibitors as a potential risk factor for fatal COVID-19, BMJ
Tang, Li, Wang, Sun, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J Thromb Haemost
Vaduganathan, Vardeny, Michel, Mcmurray, Pfeffer et al., Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19, N Engl J Med
Wang, He, Yu, Hu, Bao et al., Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up, J Infect
Wang, Hu, Hu, Zhu, Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA
Who Director, General's opening remarks at the media briefing on COVID-19-11
Wu, Chen, Chan, The outbreak of COVID-19: An overview, J Chin Med Assoc
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72?314 cases from the Chinese Center for Disease Control and Prevention, JAMA
Yang, Yu, Xu, Shu, Xia et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study, Lancet Respir Med
Zhang, Dong, Cao, Yuan, Yang et al., Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China, Allergy
Zhang, Sun, Zeng, Peng, Jiang et al., Calcium channel blocker amlodipine besylate is associated with reduced case fatality rate of COVID-19 patients with hypertension, medRxiv, doi:10.1101/2020
Zhang, Zhu, Cai, Lei, Qin et al., Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers with mortality among patients with hypertension hospitalized with COVID-19, Circ Res
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit